Opexa Therapeutics, Inc., a biotechnology company based in The Woodlands, Texas, has announced that their President and Chief Executive Officer, Neil K. Warma, will be presenting at The Second International Vatican Adult Stem Cell Conference: Regenerative Medicine — A Fundamental Shift in Science & Culture, to be held at The Vatican this April 11-13, 2013. Opexa is known for its leading product, TcelnaTM, which individuals afflicted with multiple scelerosis can benefit largely from.
This annual conference is one of the fruits of a five-year collaboration between The Stem for Life Foundation, a non-profit organization that aims to raise awareness of adult stem cell therapy; NeoStem, a forerunner in the cellular therapy industry; and The Vatican’s Pontifical Council for Culture, alongside its foundation, Science, Theology and the Ontological Quest (STOQ) International. This adult stem cell conference seeks to promote awareness of current available therapies, and clarify information regarding stem cell therapy by means of providing a venue for discussion.
Warma shares in a recent press release:
“Opexa is proud to be a part of this international forum designed to highlight the important contributions made by the cell therapy industry to date and to increase awareness of cellular research and the potential of cell therapies to address unmet medical needs.”
A month ago, Warma also presented at the 6th Annual European Life Science CEO Forum in Switzerland about the TcelnaTM. Opexa recently released its 2012 fiscal year financial results, showing a drop in their year-end finances, which they attributed to “increases in research and development, the increase in labor related to clinical trials and administrative costs, interest expenses, and depreciation on equipment value.”
Read more on BioNews Texas.